Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright

Prime Medicine, Inc. (NASDAQ:PRME) – Stock analysts at HC Wainwright raised their Q3 2026 earnings estimates for Prime Medicine in a report released on Monday, August 10th. HC Wainwright analyst A. He now forecasts that the company will earn ($0.28) per share for the quarter, up from their prior estimate of ($0.29). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Prime Medicine’s Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.11) EPS, Q2 2027 earnings at ($0.23) EPS, FY2027 earnings at ($0.91) EPS, FY2028 earnings at ($0.92) EPS, FY2029 earnings at ($0.96) EPS and FY2030 earnings at ($0.81) EPS.

Several other research firms have also recently issued reports on PRME. Wall Street Zen upgraded Prime Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday. Citigroup reissued a “market outperform” rating on shares of Prime Medicine in a report on Monday, June 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prime Medicine in a research note on Wednesday, June 3rd. TD Cowen reiterated a “buy” rating on shares of Prime Medicine in a research report on Wednesday, July 8th. Finally, The Goldman Sachs Group set a $6.00 price objective on Prime Medicine in a report on Monday, June 22nd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.53.

Prime Medicine Stock Up 3.5%

PRME opened at $3.26 on Wednesday. Prime Medicine has a twelve month low of $2.67 and a twelve month high of $6.94. The company has a 50-day moving average price of $3.27 and a 200 day moving average price of $3.47. The company has a market cap of $591.30 million, a PE ratio of -3.08 and a beta of 2.31.

Prime Medicine (NASDAQ:PRME) last announced its earnings results on Thursday, August 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.24). The business had revenue of $1.15 million for the quarter, compared to analyst estimates of $4.40 million. Prime Medicine had a negative net margin of 4,613.11% and a negative return on equity of 156.84%.

Institutional Investors Weigh In On Prime Medicine

Hedge funds and other institutional investors have recently bought and sold shares of the company. Alphabet Inc. purchased a new stake in shares of Prime Medicine in the 2nd quarter valued at approximately $61,116,000. BlackRock Inc. acquired a new stake in shares of Prime Medicine during the 2nd quarter worth approximately $35,432,000. State Street Corp raised its position in shares of Prime Medicine by 293.0% during the 4th quarter. State Street Corp now owns 5,095,510 shares of the company’s stock valued at $17,681,000 after buying an additional 3,798,884 shares during the period. Vanguard Group Inc. lifted its holdings in Prime Medicine by 35.7% in the third quarter. Vanguard Group Inc. now owns 4,921,865 shares of the company’s stock valued at $27,267,000 after acquiring an additional 1,294,355 shares during the last quarter. Finally, Balyasny Asset Management L.P. lifted its holdings in Prime Medicine by 6,426.4% in the fourth quarter. Balyasny Asset Management L.P. now owns 3,124,362 shares of the company’s stock valued at $10,842,000 after acquiring an additional 3,076,489 shares during the last quarter. 70.37% of the stock is currently owned by institutional investors and hedge funds.

Key Prime Medicine News

Here are the key news stories impacting Prime Medicine this week:

• Positive Sentiment: Prime Medicine announced that it is advancing PM577 into a first-in-human clinical study for Wilson disease. Progress toward human testing could improve investor confidence in the company’s prime-editing platform and pipeline. Prime Medicine Advances First-in-Human Prime Editing Trial in Wilson Disease
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $8.00 price target for PRME, substantially above the stock’s referenced $3.26 price. The continued bullish rating provides a positive analyst signal despite ongoing losses. HC Wainwright Reaffirms Buy Rating for Prime Medicine
• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast from a loss of $1.17 to a loss of $1.11 and improved its FY2028 forecast from a loss of $1.01 to $0.92 per share, suggesting modestly better long-term cost or earnings expectations in those periods.
• Neutral Sentiment: HC Wainwright made only minor adjustments to several forecasts, including a slightly better Q3 2026 estimate of a $0.28 loss, but maintained expectations for continued losses through 2030. The changes are unlikely to materially alter the near-term valuation story.
• Neutral Sentiment: The reported short-interest data showed zero shares sold short both before and after the measurement period, making the figures unusable for identifying meaningful short-covering or short-squeeze pressure.
• Negative Sentiment: HC Wainwright lowered its estimates for Q2 2027, Q4 2026, FY2027, FY2029 and FY2030. The largest revisions were FY2029, to a $0.96 loss from $0.85, and FY2030, to a $0.81 loss from $0.67, reinforcing concerns about prolonged cash burn and delayed profitability.

Prime Medicine Company Profile

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.